Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2017 | Pages:
103 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Pipeline Review, H2 2017 Summary Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) pipeline Target constitutes close to 32 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Transient Receptor Potential Cation Channel Subfamily V Member 1 - Pipeline Review, H2 2017, outlays comprehensive information on the Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - The transient receptor potential cation channel subfamily V member 1 (TrpV1) is a protein encoded by the TRPV1 gene. It belongs to a sub-family of the transient receptor potential protein group. It mediates proton influx and may be involved in intracellular acidosis in nociceptive neurons. It is involved in mediation of inflammatory pain and hyperalgesia. It sensitized by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases, which involves PKC isozymes and PCL. It is activated by endogenous compounds, including 12-hydroperoxytetraenoic acid and bradykinin. It acts as ionotropic endocannabinoid receptor with central neuromodulatory effects. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 9, 5, 6 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 6 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Musculoskeletal Disorders, Cardiovascular, Metabolic Disorders, Ophthalmology, Dermatology, Oncology, Respiratory, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones, Immunology and Infectious Disease which include indications Cancer Pain, Inflammatory Pain, Muscle Spasm, Muscle Spasticity, Neuropathic Pain, Pain, Postherpetic Neuralgia, Chronic Pain, Osteoarthritis Pain, Abdominal Pain, Diabetic Peripheral Neuropathy, Keratoconjunctivitis sicca (Dry Eye), Pruritus, Acute Pain, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Atherosclerosis, Atopic Dermatitis, Breast Cancer, Charcot-Marie-Tooth Disease, Chronic Cough, Cluster Headache Syndrome, Congestive Heart Failure (Heart Failure), Cough, Crohn's Disease (Regional Enteritis), Fungal Infections, Hypertension, Inflammation, Insomnia, Memory Impairment, Morton Metatarsalgia, Motor Neuron Diseases, Multiple Sclerosis, Neuro Muscular Disorders, Ocular Hypertension, Ocular Pain, Open-Angle Glaucoma, Overactive Bladder, Primary Lateral Sclerosis, Progressive Muscular Atrophy, Prostate Cancer, Radiculopathy, Rosacea, Seborrhea, Squamous Cell Carcinoma and Type 2 Diabetes. Furthermore, this report also reviews key players involved in Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - The report reviews Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics and enlists all their major and minor projects - The report assesses Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Overview Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Companies Involved in Therapeutics Development Amgen Inc Amorepacific Corp AnaBios Corp BCN Peptides SA Daewoong Pharmaceutical Co Ltd DoNatur GmbH Flex Pharma Inc Grunenthal GmbH Kyowa Hakko Kirin Co Ltd Medifron DBT Co Ltd Neurim Pharmaceuticals Ltd Pila Pharma AB Sylentis SAU Toray Industries Inc Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Drug Profiles AMG-986 - Drug Profile Product Description Mechanism Of Action R&D Progress BK-1119 - Drug Profile Product Description Mechanism Of Action R&D Progress capsaicin - Drug Profile Product Description Mechanism Of Action R&D Progress capsaicin - Drug Profile Product Description Mechanism Of Action R&D Progress CMX-020 - Drug Profile Product Description Mechanism Of Action R&D Progress DD-04107 - Drug Profile Product Description Mechanism Of Action R&D Progress DWP-05195 - Drug Profile Product Description Mechanism Of Action R&D Progress FLX-787 - Drug Profile Product Description Mechanism Of Action R&D Progress FLX-788 - Drug Profile Product Description Mechanism Of Action R&D Progress FLX-797 - Drug Profile Product Description Mechanism Of Action R&D Progress FLX-798 - Drug Profile Product Description Mechanism Of Action R&D Progress K-685 - Drug Profile Product Description Mechanism Of Action R&D Progress MCS-18 - Drug Profile Product Description Mechanism Of Action R&D Progress MDR-16523 - Drug Profile Product Description Mechanism Of Action R&D Progress MDR-652 - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibodies to Inhibit TRPV1 for Inflammatory Pain and Cancer Pain - Drug Profile Product Description Mechanism Of Action R&D Progress NEO-6860 - Drug Profile Product Description Mechanism Of Action R&D Progress NeuP-12 - Drug Profile Product Description Mechanism Of Action R&D Progress PAC-14028 - Drug Profile Product Description Mechanism Of Action R&D Progress Peptides to Target TRPV1 for Pain and Itch - Drug Profile Product Description Mechanism Of Action R&D Progress piromelatine - Drug Profile Product Description Mechanism Of Action R&D Progress QX-314 - Drug Profile Product Description Mechanism Of Action R&D Progress resiniferatoxin - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Block TRPV1 for Overactive Bladder - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Block TRPV1 for Pain - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Block TRPV1 for Pain - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Activate TRPV1 Channel for Pain and Inflammation - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Block TRPA1 and TRPV1 for Central Nervous System - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Block TRPA1 and TRPV1 for Pain - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Block TRPV1 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress SYL-1001 - Drug Profile Product Description Mechanism Of Action R&D Progress XEND-0501 - Drug Profile Product Description Mechanism Of Action R&D Progress zucapsaicin - Drug Profile Product Description Mechanism Of Action R&D Progress Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Dormant Products Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Discontinued Products Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Product Development Milestones Featured News & Press Releases Aug 01, 2017: Flex Pharma Initiates ALS Phase 2 Trial with FLX-787 in US Jul 25, 2017: FDA Grants Fast Track Designation to Flex Pharma's FLX-787 for the Treatment of Severe Muscle Cramps Associated with ALS Jul 20, 2017: Centrexion Therapeutics to Present Phase 2b Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Morton's Neuroma at the American Podiatric Medical Association 2017 Annual Scientific Meeting Jun 29, 2017: Sorrento Therapeutics Announced FDA Authorization of IND to Commence Clinical Trial of RTX in Intractable Cancer Pain Jun 13, 2017: Centrexion Therapeutics Announces New 6-Month Data Demonstrating Significant and Durable Pain Relief with CNTX-4975 for Treatment of Moderate to Severe Knee Osteoarthritis Pain Jun 07, 2017: Centrexion Therapeutics Announces Oral Presentation of Six Month Efficacy Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at the Annual European Congress of Rheumatology Jun 02, 2017: Flex Pharmas Phase 2 Trial with FLX-787 in Charcot-Marie-Tooth Endorsed by the Inherited Neuropathies Consortium May 30, 2017: Sylentis initiates a Phase III study for the treatment of dry eye syndrome May 25, 2017: Centrexion Therapeutics to Present Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at European Federation of National Associations of Orthopaedics and Traumatologys 2017 Annual Congress May 10, 2017: Centrexion Therapeutics to Present Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Morton's Neuroma and Knee Osteoarthritis at American Pain Society 2017 Annual Scientific Meeting May 09, 2017: PharmaMar: Sylentis Announces New Preclinical and Clinical Data for its SYL1001 Molecule During ARVO 2017 Apr 26, 2017: FDA Clears Flex Pharmas FLX-787 to Commence US Phase 2 Trial in ALS Under IND Apr 19, 2017: Flex Pharma Presents Human Efficacy Data on FLX-787 at the American Academy of Neurology Annual Meeting Apr 05, 2017: Flex Pharma Names William K. McVicar, Ph.D. as President, Research & Development Mar 23, 2017: Centrexion Therapeutics to Present Data on CNTX-4975 from the Treatment of Knee Osteoarthritis Pain at IX SIMPAR-ISURA Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables Number of Products under Development by Stage of Development, H2 2017 Number of Products under Development by Therapy Areas, H2 2017 Number of Products under Development by Indications, H2 2017 Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 Number of Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Companies, H2 2017 (Contd..3), H2 2017 Number of Products under Investigation by Universities/Institutes, H2 2017 Products under Investigation by Universities/Institutes, H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Pipeline by Amgen Inc, H2 2017 Pipeline by Amorepacific Corp, H2 2017 Pipeline by AnaBios Corp, H2 2017 Pipeline by BCN Peptides SA, H2 2017 Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017 Pipeline by DoNatur GmbH, H2 2017 Pipeline by Flex Pharma Inc, H2 2017 Pipeline by Grunenthal GmbH, H2 2017 Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017 Pipeline by Medifron DBT Co Ltd, H2 2017 Pipeline by Neurim Pharmaceuticals Ltd, H2 2017 Pipeline by Pila Pharma AB, H2 2017 Pipeline by Sylentis SAU, H2 2017 Pipeline by Toray Industries Inc, H2 2017 Dormant Products, H2 2017 Dormant Products, H2 2017 (Contd..1), H2 2017 Dormant Products, H2 2017 (Contd..2), H2 2017 Dormant Products, H2 2017 (Contd..3), H2 2017 Dormant Products, H2 2017 (Contd..4), H2 2017 Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
